{"id":1020,"date":"2026-11-19T00:02:33","date_gmt":"2026-11-18T23:02:33","guid":{"rendered":"https:\/\/event.eortc.org\/ena2026\/?p=1020"},"modified":"2026-11-19T09:32:23","modified_gmt":"2026-11-19T08:32:23","slug":"new-drug-iacs-6274-shows-promise-in-phase-i-clinical-trial-treating-patients-with-advanced-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/new-drug-iacs-6274-shows-promise-in-phase-i-clinical-trial-treating-patients-with-advanced-ovarian-cancer\/","title":{"rendered":"New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:63px;--awb-border-radius-top-right:63px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-overflow:hidden;--awb-padding-bottom:0px;--awb-margin-top:-63px;--awb-margin-bottom:0px;--awb-margin-top-small:-53px;--awb-background-color:var(--awb-color6);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-end fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-color:var(--awb-color6);--awb-bg-color-hover:var(--awb-color6);--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:8%;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\" data-scroll-devices=\"small-visibility,medium-visibility,large-visibility\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_3_4 3_4 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:75%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.56%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.56%;--awb-width-medium:75%;--awb-order-medium:0;--awb-spacing-right-medium:2.56%;--awb-spacing-left-medium:2.56%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><h3>New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer<\/h3>\n<p><strong>19 November, Barcelona, Spain<\/strong>: Patients with advanced, hard-to-treat ovarian cancer have responded well to treatment with a drug called IACS-6274 when combined with the targeted therapy bevacizumab and paclitaxel chemotherapy.<\/p>\n<div>\n<p>Results from a phase I clinical trial in 14 patients, presented on Thursday at the 38th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, showed the combination was safe, and that nine out of 13 patients (69%) with tumours that could be measured during scans had confirmed partial responses in which the tumours shrank by at least 30%. Three patients had stable disease, in which the cancer neither grew nor shrank. One patient had early clinical progression of their disease so there were no further scans to re-stage the tumour, and they left the trial.<\/p>\n<p>Twelve weeks after treatment started, cancer remained under control for 11 out of 13 patients (85%), and the duration of treatments lasted beyond 37 months in a subset of patients.<\/p>\n<p>The trial was led by Timothy Yap, professor of Investigational Cancer Therapeutics and vice president and head of clinical development in the Therapeutics Discovery division at The University of Texas MD Anderson Cancer Center, USA, where IACS-6274 was invented and where the trial was conducted.<\/p>\n<p>He said: \u201cWe observed deep and very durable responses in patients with advanced, hard-to-treat ovarian cancer. Patients also reported an improvement in their cancer-related symptoms. In ten out of 13 patients (77%) with radiological measurable disease, we observed durable tumour regression with partial responses or stable disease lasting four months or more.\u201d<\/p>\n<p>Only about 15% of women diagnosed with advanced ovarian cancer will survive for at least five years and often they will have received several different anti-cancer therapies to treat it.<\/p>\n<p>Prof. Yap said: \u201cOvarian cancer often adapts to approved standard-of-care anti-cancer therapies, such as bevacizumab and chemotherapy, by switching its diet to rely heavily on a nutrient called glutamine to survive and grow. In this way, the cancer becomes resistant to treatments. We have carried out research in the laboratory that showed that blocking this glutamine pathway with a glutaminase-1 (GLS1) inhibitor drug successfully shrank these resistant tumours, especially when combined with bevacizumab and chemotherapy.<\/p>\n<p>\u201cThese promising results provided the rationale to design and conduct a clinical trial to test the safety, tolerability and preliminary anti-tumour activity of the GLS1 inhibitor, IACS-6274, in combination with bevacizumab and paclitaxel chemotherapy in patients whose ovarian cancers have stopped responding to standard treatment.\u201d<\/p>\n<p>A total of 14 patients with advanced ovarian cancer and with an average age of 56 years (range 45-75 years), received 120 mg or 180 mg of IACS-6274 orally, twice a day throughout the trial, together with bevacizumab (10 mg\/Kg on days one and 15) and paclitaxel chemotherapy (80 mg\/m2 on days one, eight and 15) given intravenously in 21-day cycles. Tumours in 13 out of 14 patients (93%) had failed to respond to platinum-based therapies.<\/p>\n<p>The researchers also took tumour and blood samples to analyse them for an enzyme called ASNS, as well as changes to genes and various cell communication pathways.<\/p>\n<p>\u201cSome cancers lack a specific enzyme called ASNS, which leaves them with only one backup supply line for the nutrients they need to survive. The GLS1 inhibitor, IACS-6274, works by blocking that exact backup supply line, essentially starving and destroying the tumour cells while leaving healthy cells unharmed,\u201d said Prof. Yap. \u201cIn this group of patients, eight out of 14 (57%) had ASNS loss.\u201d<\/p>\n<p>Both dose levels were well-tolerated. Common, mild, adverse side effects included nausea, fatigue, hair loss, anaemia, nose bleeds, elevated levels of the enzymes ALT\/AST that indicate the liver is under stress, reduced white blood cell count (neutropenia), nail disorders and vision disturbances (photopsia). More serious side effects, which were treated successfully, included neutropenia, elevated blood pressure and anaemia. No patients suffered any side effects that limited the level of the treatment dose.<\/p>\n<p>\u201cAnalysis of the tumour and blood samples in the laboratory showed that the treatment also reshaped the tumour microenvironment toward greater activation of the immune system, while ASNS loss was associated with a high response rate, providing a potential predictive biomarker of response to the drug combination, which we will study further in the clinic. Notably, six out of the eight patients with tumours lacking ASNS achieved radiological partial responses,\u201d said Prof. Yap.<\/p>\n<p>The analyses also revealed another way that cancer cells can become resistant to treatment and start to spread around the body, a process called epithelial-to-mesenchymal transition (EMT).<\/p>\n<p>\u201cOur findings suggest that tumours undergoing an EMT-like transition may adapt to GLS1 inhibition by activating the ASNS pathway as an alternative metabolic survival mechanism. If validated, this could provide the rationale for combining GLS1 inhibition with strategies targeting this compensatory pathway to prevent or overcome resistance,\u201d said Prof. Yap.<\/p>\n<p>The researchers have started to treat an increased number of patients with advanced ovarian cancer. A further 15 patients will be treated, followed by another 15 patients if the treatment continues to be effective.<\/p>\n<p>Strengths of the trial include the fact that researchers are collecting tumour and blood samples throughout the duration of the study, so that they can conduct \u2018reverse translational studies\u2019 in the laboratory to understand why some patients respond to the treatment while others do not. A limitation is that only a small number of patients have been treated so far in order to achieve early, proof-of-concept for the drug combination and to support the two-stage expansion phase of the trial.<\/p>\n<p>Professor Elena Garralda, chair of the EORTC-NCI-AACR Symposium and co-director of the Vall d\u2019Hebron Institute of Oncology\u2019s clinical research programme, was not involved with the study. She commented: \u201cAdvanced ovarian cancer is very hard to treat successfully, so the results from this phase I clinical trial of IACS-6274, in combination with two existing therapies for the disease, are encouraging. These results are especially significant as the patients had received several other previous treatments and their tumours had not responded to them. We look forward to results from the expanded phase I trial and, if these are promising, to IACS-6274 being taken forward into phase II and III clinical trials.<\/p>\n<p>\u201cThis research is also a very good example of how work carried out in the laboratory can translate to potentially better treatments for patients, with the clinical results taken back to the lab to be investigated further \u2013 a process of \u2018reverse translation\u2019 that help us understand the biological mechanisms underpinning the cancer and its response to targeted drugs.\u201d<\/p>\n<p><a href=\"https:\/\/cm.eortc.org\/cmPortal\/Searchable\/ena2026\/config\/Normal#!sessiondetails\/0000115140_0\" target=\"_blank\" rel=\"noopener\">Abstract no: 1, \u201cPhase 1 trial and translational study of the glutaminase-1 (GLS1) inhibitor IACS-6274 in combination with bevacizumab and paclitaxel in patients with advanced ovarian cancer\u201d, by Tim Yap, presented in proffered papers plenary session 2, 10:00-11:30 hrs, rooms 111+112, Thursday 19 November 2026<\/a><\/p>\n<p><sup>[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research]. The Symposium takes place in Barcelona from 18-20 November 2026.<\/sup><\/p>\n<p><sup>This study was funded by The University of Texas MD Anderson Cancer Center where IACS-6274 was invented.<\/sup><\/p>\n<\/div>\n<\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_4 1_4 fusion-flex-column invisible\" style=\"--awb-bg-size:cover;--awb-width-large:25%;--awb-margin-top-large:18px;--awb-spacing-right-large:7.68%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:7.68%;--awb-width-medium:25%;--awb-order-medium:0;--awb-spacing-right-medium:7.68%;--awb-spacing-left-medium:7.68%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\" data-scroll-devices=\"small-visibility,medium-visibility,large-visibility\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-text-color:var(--awb-color1);--awb-margin-top-small:10px;--awb-margin-right-small:0px;--awb-margin-bottom-small:10px;--awb-margin-left-small:0px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Recent posts<\/h4><\/div><div class=\"fusion-recent-posts fusion-recent-posts-1 avada-container layout-default layout-columns-1 invisible\"><section class=\"fusion-columns columns fusion-columns-1 columns-1\"><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:49:07+01:00<\/span><h4 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/antibody-drug-conjugate-shows-promising-early-results-in-phase-i-trial-in-sarcoma-patients\/\">Antibody-drug conjugate shows promising early results in phase I trial in sarcoma patients<\/a><\/h4><p>   Antibody-drug conjugate shows promising early results in phase I trial in sarcoma patients 19 November Barcelona, Spain: An antibody-drug conjugate, a type of drug that targets and enters cancer cells like a [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:32:23+01:00<\/span><h4 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/new-drug-iacs-6274-shows-promise-in-phase-i-clinical-trial-treating-patients-with-advanced-ovarian-cancer\/\">New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer<\/a><\/h4><p>    New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer 19 November, Barcelona, Spain: Patients with advanced, hard-to-treat ovarian cancer have responded well to treatment [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:53:26+01:00<\/span><h4 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/antibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results\/\">Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results<\/a><\/h4><p>    Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results in phase I head and neck cancer trial 19 November, Barcelona, Spain: An antibody-drug conjugate (ADC), called micvotabart pelidotin, or MICVO, [...]<\/p><\/div><\/article><\/section><\/div><div class=\"fusion-sharing-box fusion-sharing-box-1 has-taglines layout-stacked layout-medium-stacked layout-small-stacked\" style=\"background-color:var(--awb-color5);border-color:#cccccc;--awb-separator-border-color:#cccccc;--awb-separator-border-sizes:0px;--awb-layout:column;--awb-alignment-small:space-between;--awb-stacked-align-small:center;\" data-title=\"Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results\" data-description=\"Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results in phase I head and neck cancer trial\r\n19 November, Barcelona, Spain: An antibody-drug conjugate (ADC), called micvotabart pelidotin, or MICVO, has produced positive results in an early trial with head and neck cancer patients.\r\n\r\nThe results, to be presented on Thursday at the\" data-link=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/antibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results\/\"><h4 class=\"tagline\" style=\"color:var(--awb-color8);\">Share This Story<\/h4><div class=\"fusion-social-networks sharingbox-shortcode-icon-wrapper sharingbox-shortcode-icon-wrapper-1\"><span><a href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fevent.eortc.org%2Fena2026%2F2026%2F11%2F19%2Fantibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results%2F\" target=\"_blank\" rel=\"noreferrer\" title=\"Facebook\" aria-label=\"Facebook\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"Facebook\" data-><i class=\"fusion-social-network-icon fusion-tooltip fusion-facebook awb-icon-facebook\" style=\"color:var(--awb-color8);\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/x.com\/intent\/post?text=Antibody-drug%20conjugate%20designed%20to%20target%20tumour%20%E2%80%98scaffolding%E2%80%99%20produces%20positive%20results&amp;url=https%3A%2F%2Fevent.eortc.org%2Fena2026%2F2026%2F11%2F19%2Fantibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"X\" aria-label=\"X\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"X\" data-><i class=\"fusion-social-network-icon fusion-tooltip fusion-twitter awb-icon-twitter\" style=\"color:var(--awb-color8);\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/www.linkedin.com\/sharing\/share-offsite\/?url=https%3A%2F%2Fevent.eortc.org%2Fena2026%2F2026%2F11%2F19%2Fantibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"LinkedIn\" aria-label=\"LinkedIn\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"LinkedIn\" data-><i class=\"fusion-social-network-icon fusion-tooltip fusion-linkedin awb-icon-linkedin\" style=\"color:var(--awb-color8);\" aria-hidden=\"true\"><\/i><\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1020","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/posts\/1020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/comments?post=1020"}],"version-history":[{"count":5,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/posts\/1020\/revisions"}],"predecessor-version":[{"id":1087,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/posts\/1020\/revisions\/1087"}],"wp:attachment":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/media?parent=1020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/categories?post=1020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/tags?post=1020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}